BioLife
Financials
2021 FY Annual Revenue
$30.17 Billion
2021 FY Gross Profit
$20.79 Billion
2021 FY Annual Net Income
$3.55 Billion
2021 FY Gross Profit Growth
2.67%
2021 Number of U.S. Stores
180
Credit Rating
Leases guaranteed by Baxalta, Inc., which senior unsecured notes are Investment Grade BBB+
BioLife
BioLife Plasma Services is a leading company for high-quality plasma collection. A part of a global biopharmaceutical company, Takeda Pharmaceutical Compnay Limited (NYSE:TAK), BioLife continues to use high-quality plasma for the benefit of those in need. The financials and credit ratings presented are representative of the consolidated results of Takeda Pharmaceutical Company, which is BioLife Plasma Services’s parent entity.